+

WO2008113255A1 - Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques - Google Patents

Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques Download PDF

Info

Publication number
WO2008113255A1
WO2008113255A1 PCT/CN2008/000500 CN2008000500W WO2008113255A1 WO 2008113255 A1 WO2008113255 A1 WO 2008113255A1 CN 2008000500 W CN2008000500 W CN 2008000500W WO 2008113255 A1 WO2008113255 A1 WO 2008113255A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
formula
alkoxy
compound according
Prior art date
Application number
PCT/CN2008/000500
Other languages
English (en)
Chinese (zh)
Inventor
Shuxin Li
Yongxue Liu
Yanjin Zhao
Chunguang Han
Xianzhao Kuang
Linyi Huang
Wensong Xiao
Xiaomei Sun
Xiaodong Deng
Yang Xue
Qingquan Ye
Original Assignee
The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla filed Critical The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla
Priority to CN2008800159294A priority Critical patent/CN101730703B/zh
Publication of WO2008113255A1 publication Critical patent/WO2008113255A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • MS-275 is the first histone deacetylase inhibitor that has been shown to have oral anticancer activity in animals.
  • MS-275 is undergoing clinical studies of leukemia and solid tumors in the United States.
  • some new compounds with better performance have yet to be developed in order to obtain HDAC inhibitors with high anticancer activity, small side effects and more stability.
  • Another object of the present invention is to provide a process for the preparation of the above compound or a pharmaceutically acceptable acid salt thereof.
  • R 2 is hydrogen or C r C 4 alkyl
  • L is S or NH
  • E is N or C-A
  • Gi is -S-C3 ⁇ 4- or -SC(CH 3 )(H)-;
  • J is selected from the following groups:
  • X 2 is selected from fluorine or dC 4 alkoxy
  • Preferred compounds of formula (I) of the invention have the structure of formula (IG):
  • X 2 is selected from fluorine or C, -C 4 alkoxy
  • R4 is hydrogen or C r C 6 alkyl.
  • Hetl is an aryl or heteroaryl group which may be optionally substituted, each group may be arbitrarily combined with one or more aryl or heterocyclic groups, or with one or more saturated or partially unsaturated cycloalkyl or hetero Ring, each ring can be arbitrarily substituted;
  • the present invention also provides a process for the preparation of the benzamide derivatives of the present invention.
  • the solvent used in the above preparation method may be selected from various options such as chloroform, dichlorodecane, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, xylene, toluene, dimethyl sulfoxide. , triethylamine, and other organic solvents; the reaction temperature is -30 - +80 ° C; if necessary, a base such as sodium hydroxide, triethylamine, pyridine, etc. may be added, such as hydrochloric acid, acetic acid, trifluoroacetic acid and the like.
  • Step 3 Synthesis of N-(2-amino-5-fluorophenyl)-3-(4-((4-decyloxyphenylamino)methyl)phenyl acrylamide (Compound 39).
  • 1.44g of N,N-carbonyldiimidazole was dissolved in 10ml of anhydrous tetrahydrofuran, reacted at 45 ° C for 1.5h, cooled, and set aside.
  • 1.33g of 4-fluoro-1, 2-Phenylenediamine is dissolved in anhydrous tetrahydrofuran, l.Olg trifluoroacetic acid is added dropwise, and the reaction mixture is added dropwise.
  • the product has a melting point of m.p. 219.5-221 °C;
  • the melting point of the product is m.p. 165-167 ° C;
  • the product has a melting point of m.p. 212-215 ° C;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de benzamide de formule I. Les définitions des substituants Het, G1, G2, G3, Y, X1, X2, X3 et X4 sont données dans la description. L'invention concerne également des procédés de préparation de ces composés, des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés en tant que principes actifs dans des médicaments pour le traitement de maladies associées avec la prolifération, par exemple la leucémie et les tumeurs solides.
PCT/CN2008/000500 2007-03-16 2008-03-14 Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques WO2008113255A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008800159294A CN101730703B (zh) 2007-03-16 2008-03-14 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200710086587.2 2007-03-16
CN200710086587 2007-03-16
CN200710143940.6 2007-08-15
CN200710143940 2007-08-15

Publications (1)

Publication Number Publication Date
WO2008113255A1 true WO2008113255A1 (fr) 2008-09-25

Family

ID=39765375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/000500 WO2008113255A1 (fr) 2007-03-16 2008-03-14 Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques

Country Status (2)

Country Link
CN (2) CN101730703B (fr)
WO (1) WO2008113255A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064737A1 (fr) * 2009-02-16 2010-06-10 Nishio Tetsuya Composé hétérocyclique et son utilisation
WO2012149528A1 (fr) * 2011-04-29 2012-11-01 Exelixis, Inc. Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase
CN102775356A (zh) * 2011-05-13 2012-11-14 江苏恒谊药业有限公司 4-氨基喹唑啉衍生物及其应用
WO2013004332A1 (fr) * 2011-07-07 2013-01-10 Merck Patent Gmbh Azahétérocycles substitués pour le traitement du cancer
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2015006875A1 (fr) * 2013-07-18 2015-01-22 Methylgene Inc. Procédé de préparation de pyrimidines substituées
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP2015528812A (ja) * 2012-07-27 2015-10-01 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9499496B2 (en) 2012-06-05 2016-11-22 University Of Kansas Inhibitors of respiratory syncytial virus
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9902728B2 (en) 2014-12-30 2018-02-27 Forma Therapeutics, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10000495B2 (en) 2014-12-30 2018-06-19 Forma Therapeutics, Inc. Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10172840B2 (en) 2014-12-01 2019-01-08 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10662199B2 (en) 2011-04-28 2020-05-26 The Broad Institute, Inc. Inhibitors of histone deacetylase
US10793538B2 (en) 2012-12-20 2020-10-06 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
EP4100109A4 (fr) * 2020-02-06 2024-03-27 Children's Hospital Medical Center Composés, compositions, méthodes pour le traitement de maladies et de lésions nerveuses et procédés pour la préparation de composés
US12091407B2 (en) 2010-02-18 2024-09-17 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US12128018B2 (en) 2018-01-12 2024-10-29 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128276A (ja) * 1992-10-20 1994-05-10 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
WO2001002369A2 (fr) * 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci
WO2003064385A2 (fr) * 2002-02-01 2003-08-07 Bayer Cropscience Ag Delta1-pyrrolines
WO2005030705A1 (fr) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
US20050187300A1 (en) * 2002-07-15 2005-08-25 Myriad Genetics, Incorporated Compounds, compositions, and methods employing same
WO2005092899A1 (fr) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibiteurs d'histone désacétylase
WO2006115845A1 (fr) * 2005-04-20 2006-11-02 Merck & Co., Inc. Derives du benzothiophene
WO2006122319A2 (fr) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
WO2007002559A1 (fr) * 2005-06-27 2007-01-04 Exelixis, Inc. Modulateurs des lxr a base de pyrazoles
US20070015809A1 (en) * 2005-07-14 2007-01-18 Bressi Jerome C Histone deacetylase inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128276A (ja) * 1992-10-20 1994-05-10 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
WO2001002369A2 (fr) * 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci
WO2003064385A2 (fr) * 2002-02-01 2003-08-07 Bayer Cropscience Ag Delta1-pyrrolines
US20050187300A1 (en) * 2002-07-15 2005-08-25 Myriad Genetics, Incorporated Compounds, compositions, and methods employing same
WO2005030705A1 (fr) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005030704A1 (fr) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005092899A1 (fr) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibiteurs d'histone désacétylase
WO2006115845A1 (fr) * 2005-04-20 2006-11-02 Merck & Co., Inc. Derives du benzothiophene
WO2006122319A2 (fr) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
WO2007002559A1 (fr) * 2005-06-27 2007-01-04 Exelixis, Inc. Modulateurs des lxr a base de pyrazoles
US20070015809A1 (en) * 2005-07-14 2007-01-18 Bressi Jerome C Histone deacetylase inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMICAL ABSTRACTS [online] 2001, Database accession no. (134:353234) *
DATABASE CHEMICAL ABSTRACTS [online] 2002, Database accession no. (136:34497) *
DATABASE CHEMICAL ABSTRACTS [online] 2002, Database accession no. (137:164950) *
KRAL'OVA K. ET AL.: "Inhibition of oxygen evolution rate in fresh water algae Chlorella vulgaris by some anilides of substituted pyridine-4-carboxylic acids", CHEMICAL PAPERS, vol. 55, no. 4, 2001, pages 251 - 253 *
MILETIN M. ET AL.: "Inhibition of oxygen evolution rate in spinach chloroplasts by some anilides of substitutedpyridine-4-carboxylic acids", FOLIA PHARMACEUTICA UNIVERSITATIS CAROLINAE, vol. 26, 2001, pages 27 - 32 *
MILETIN M. ET AL.: "Some anilides of 2-alkylthio- and 2-chloro-6-alkylthio-4-pyridinecarboxylic acids: synthesis and photosynthesis-inhibiting activity", MOLECULES, vol. 6, no. 7, 2001, pages 603 - 613, XP055014285, Retrieved from the Internet <URL:http://www.mdpi.org/molecules/papers/60700603.pdf> DOI: doi:10.3390/60700603 *
NAZAROV V.N. ET AL.: "Acylation of amines by diphenic anhydride", VESTNIK NATSIONAL'NOGO TEKHNICHESKOGO UNIVERSITETA "KHPI", no. 12, 2006, pages 27 - 34 *

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9796664B2 (en) 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
WO2010064737A1 (fr) * 2009-02-16 2010-06-10 Nishio Tetsuya Composé hétérocyclique et son utilisation
US8895565B2 (en) 2009-02-16 2014-11-25 Tetsuya Nishio Heterocyclic compound and use of the same
US12091407B2 (en) 2010-02-18 2024-09-17 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US11649230B2 (en) 2010-02-18 2023-05-16 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US11130753B2 (en) 2010-02-18 2021-09-28 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10570126B2 (en) 2010-02-18 2020-02-25 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10287284B2 (en) 2010-02-18 2019-05-14 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10030011B2 (en) 2010-02-18 2018-07-24 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10301323B2 (en) 2011-02-28 2019-05-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10981933B2 (en) 2011-02-28 2021-04-20 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10526346B2 (en) 2011-02-28 2020-01-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9512143B2 (en) 2011-02-28 2016-12-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10280182B2 (en) 2011-02-28 2019-05-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9908899B2 (en) 2011-02-28 2018-03-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US11572368B2 (en) 2011-04-28 2023-02-07 The General Hospital Corporation Inhibitors of histone deacetylase
US10662199B2 (en) 2011-04-28 2020-05-26 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2012149528A1 (fr) * 2011-04-29 2012-11-01 Exelixis, Inc. Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase
WO2012155806A1 (fr) * 2011-05-13 2012-11-22 江苏恒谊药业有限公司 Dérivés de 4-aminoquinazoline et utilisations de ceux-ci
US20140235633A1 (en) * 2011-05-13 2014-08-21 Shanghai Institute Of Pharmaceutical Industry 4-Aminoquinazoline Derivatives and Uses Thereof
US9034886B2 (en) 2011-05-13 2015-05-19 Shanghai Institute Of Pharmaceutical Industry 4-aminoquinazoline derivatives and uses thereof
CN102775356A (zh) * 2011-05-13 2012-11-14 江苏恒谊药业有限公司 4-氨基喹唑啉衍生物及其应用
JP2014520767A (ja) * 2011-07-07 2014-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための置換されたアザ複素環
WO2013004332A1 (fr) * 2011-07-07 2013-01-10 Merck Patent Gmbh Azahétérocycles substitués pour le traitement du cancer
US9199962B2 (en) 2011-07-07 2015-12-01 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
AU2012280725B2 (en) * 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
US9499496B2 (en) 2012-06-05 2016-11-22 University Of Kansas Inhibitors of respiratory syncytial virus
US11377423B2 (en) 2012-07-27 2022-07-05 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP2015528812A (ja) * 2012-07-27 2015-10-01 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
US10793538B2 (en) 2012-12-20 2020-10-06 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
US10428028B2 (en) 2013-03-15 2019-10-01 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
WO2015006875A1 (fr) * 2013-07-18 2015-01-22 Methylgene Inc. Procédé de préparation de pyrimidines substituées
US10898475B2 (en) 2014-12-01 2021-01-26 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10463652B2 (en) 2014-12-01 2019-11-05 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10172840B2 (en) 2014-12-01 2019-01-08 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10000495B2 (en) 2014-12-30 2018-06-19 Forma Therapeutics, Inc. Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
US9902728B2 (en) 2014-12-30 2018-02-27 Forma Therapeutics, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US12018030B2 (en) 2014-12-30 2024-06-25 Valo Health, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US11795171B2 (en) 2014-12-30 2023-10-24 Valo Health, Inc. Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
US10351571B2 (en) 2014-12-30 2019-07-16 Forma Therapeutics, Inc. Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
US10981915B2 (en) 2014-12-30 2021-04-20 Valo Early Discovery, Inc. Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
US10934299B2 (en) 2014-12-30 2021-03-02 Valo Early Discovery, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US10377760B2 (en) 2014-12-30 2019-08-13 Forma Therapeutics, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US10519129B2 (en) 2015-02-05 2019-12-31 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10377773B2 (en) 2015-02-05 2019-08-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10906916B2 (en) 2015-02-05 2021-02-02 Valo Early Discovery, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10927130B2 (en) 2015-02-05 2021-02-23 Valo Early Discovery, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10513508B2 (en) 2015-02-05 2019-12-24 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10513507B2 (en) 2015-02-05 2019-12-24 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10377767B2 (en) 2015-02-05 2019-08-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10836741B2 (en) 2015-02-05 2020-11-17 Valo Early Discovery, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10508098B2 (en) 2015-02-05 2019-12-17 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10519128B2 (en) 2015-02-05 2019-12-31 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US11739071B2 (en) 2015-02-05 2023-08-29 Valo Health, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10519130B2 (en) 2015-02-05 2019-12-31 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10519127B2 (en) 2015-02-05 2019-12-31 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US12128018B2 (en) 2018-01-12 2024-10-29 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
EP4100109A4 (fr) * 2020-02-06 2024-03-27 Children's Hospital Medical Center Composés, compositions, méthodes pour le traitement de maladies et de lésions nerveuses et procédés pour la préparation de composés

Also Published As

Publication number Publication date
CN101730703A (zh) 2010-06-09
CN103087043A (zh) 2013-05-08
CN101730703B (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
WO2008113255A1 (fr) Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques
RU2453536C2 (ru) Ингибиторы гистондезацетилазы
JP2009242437A (ja) スルホンアミド誘導体
EA005373B1 (ru) Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
CN105579457B (zh) 取代的n‑联苯‑3‑乙酰基氨基‑苯甲酰胺和n‑[3‑(乙酰基氨基)苯基]‑联苯‑甲酰胺及其作为wnt信号通路抑制剂用途
CA2684037A1 (fr) Composes presentant une activite anti-cancereuse
GB2441396A (en) Indoline sulfonamide compounds
CA2601979A1 (fr) Pyrazine sulfonamides 2,3 substituees
TW200806623A (en) Anti-hypercholesterolemic compounds
BR112021014977A2 (pt) Derivados de acetamido como inibidores de dna polimerase teta
JPWO2005026127A1 (ja) プラスミノゲンアクチベータインヒビター−１阻害剤
CA2748124A1 (fr) Compositions agonistes de ppar et procedes d&#39;utilisation
CN106478606A (zh) N‑取代吲哚类衍生物及其应用
WO2008087514A2 (fr) Inhibiteurs d&#39;hdac
Zhang et al. Design, synthesis and activity evaluation of indole-based double–Branched HDAC1 inhibitors
WO2023097386A1 (fr) Composés n-acylhydrazoniques inhibiteurs sélectifs de hdac6, leurs procédés d&#39;obtention, compositions, utilisations, méthodes de traitement et trousses
TW200951110A (en) Novel N-(2-amino-phenyl)-acrylamides
JP6228667B2 (ja) 新規な抗真菌性オキソジヒドロピリジンカルボヒドラジド誘導体
KR102047816B1 (ko) 염증 및 암 치료에 유용한 비스아릴술폰아미드
CN102775381B (zh) 取代的酰肼类化合物及其制备方法、药物组合物和用途
WO2018068357A1 (fr) Nouvel inhibiteur de protéine sirt2 et son utilisation pharmaceutique
CN118420515A (zh) 具有hdac6选择性抑制活性的5-芳基-1h-吲哚衍生物及其制备方法与用途
TW200524886A (en) Carboxylic acid compound and pharmaceutical composition containg same as active ingredient
TWI619695B (zh) 蛋白酪胺酸磷酸酶ｓｈｐ－１之增效劑
TW201934547A (zh) 一種嘧啶類化合物、其製備方法及其醫藥用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015929.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08714953

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08714953

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载